Yanchun Li1, Mateusz Opyrchal2, Song Yao3, Xuan Peng4, Li Yan4, Hossam Jabbour5, Thaer Khoury6. 1. Department of Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. yancli@gmail.com. 2. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. 3. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA. 4. Department of Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA. 5. Department of Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. 6. Department of Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. Thaer.Khoury@RoswellPark.org.
Abstract
PURPOSE: The purpose of the study is to investigate the prognostic significance of programmed death ligand-1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2+ breast cancer (BC). METHODS: HER2+ BC cases (n = 191) were collected between 1996 and 2013. Tissue microarray (TMA) slides were stained with two clones of PD-L1 antibodies (28-8 and 22C3) and the percentage of positive membranous staining was scored. TILs of the full sections were also scored using percentage scale. RESULTS: Clone 28-8 had expression in ≥ 1% of the tumor cells in 25.7% of the cases, while clone 22C3 in ≥ 1% of the tumor cells was expressed in 11.5% of the cases. In the multivariate analysis, higher expression of PD-L1 (clone 28-8) in tumor correlated with lower risk of tumor recurrence, with HR of 0.4 (p = 0.033). Higher level of TILs (> 15%) predicts better overall survival (OS) in all patients with HR of 0.35 (p = 0.0046). In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, lower PD-L1 (clone 28-8) expression in TILs correlated with tumor recurrence (p = 0.034). In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, lower TILs and lower PD-L1 (clone 28-8) expression in tumor had borderline statistical significance in association with tumor recurrence (p = 0.064 and 0.083, respectively). In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, PD-L1 or TILs was not statistically significant to predict 5-year survival. In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, low TILs (p = 0.009) correlated with 5-year death due to disease. CONCLUSION: We conclude that PD-L1 may have prognostic significance in HER2+ BCs.
PURPOSE: The purpose of the study is to investigate the prognostic significance of programmed death ligand-1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2+ breast cancer (BC). METHODS:HER2+ BC cases (n = 191) were collected between 1996 and 2013. Tissue microarray (TMA) slides were stained with two clones of PD-L1 antibodies (28-8 and 22C3) and the percentage of positive membranous staining was scored. TILs of the full sections were also scored using percentage scale. RESULTS: Clone 28-8 had expression in ≥ 1% of the tumor cells in 25.7% of the cases, while clone 22C3 in ≥ 1% of the tumor cells was expressed in 11.5% of the cases. In the multivariate analysis, higher expression of PD-L1 (clone 28-8) in tumor correlated with lower risk of tumor recurrence, with HR of 0.4 (p = 0.033). Higher level of TILs (> 15%) predicts better overall survival (OS) in all patients with HR of 0.35 (p = 0.0046). In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, lower PD-L1 (clone 28-8) expression in TILs correlated with tumor recurrence (p = 0.034). In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, lower TILs and lower PD-L1 (clone 28-8) expression in tumor had borderline statistical significance in association with tumor recurrence (p = 0.064 and 0.083, respectively). In the group of patients who were treated with trastuzumab-based adjuvant chemotherapy, PD-L1 or TILs was not statistically significant to predict 5-year survival. In the group of patients who were treated with non-trastuzumab-based adjuvant chemotherapy, low TILs (p = 0.009) correlated with 5-year death due to disease. CONCLUSION: We conclude that PD-L1 may have prognostic significance in HER2+ BCs.
Entities:
Keywords:
HER2 positive breast cancer; PD-L1; Tumor-infiltrating lymphocytes
Authors: Mauricio Z Baptista; Luis Otavio Sarian; Sophie F M Derchain; Glauce A Pinto; José Vassallo Journal: Hum Pathol Date: 2015-09-25 Impact factor: 3.466
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Edith A Perez; Karla V Ballman; Kathy S Tenner; E Aubrey Thompson; Sunil S Badve; Helen Bailey; Frederick L Baehner Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: Stephen J Luen; Roberto Salgado; Stephen Fox; Peter Savas; Jennifer Eng-Wong; Emma Clark; Astrid Kiermaier; Sandra M Swain; Jose Baselga; Stefan Michiels; Sherene Loi Journal: Lancet Oncol Date: 2016-12-07 Impact factor: 41.316
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: R Barroso-Sousa; W T Barry; H Guo; D Dillon; Y B Tan; K Fuhrman; W Osmani; A Getz; M Baltay; C Dang; D Yardley; B Moy; P K Marcom; E A Mittendorf; I E Krop; E P Winer; S M Tolaney Journal: Ann Oncol Date: 2019-04-01 Impact factor: 32.976
Authors: Leiming Xia; Lu Wen; You Qin; Hannah E Dobson; Tao Zhang; Frank I Comer; Mary Jane Hinrichs; Michael D Oberst; Steven R Coats; Alfred E Chang; Yuanyuan Liu; Yangyi Bao; Fu Dai; Max S Wicha; Qiao Li Journal: Cell Chem Biol Date: 2021-03-11 Impact factor: 8.116
Authors: Hua Guo; Qingqing Ding; Yun Gong; Michael Z Gilcrease; Min Zhao; Jun Zhao; Dawen Sui; Yun Wu; Hui Chen; Hui Liu; Jinxia Zhang; Erika Resetkova; Stacy L Moulder; Wei-Lien Wang; Lei Huo Journal: Breast Cancer Res Date: 2020-06-23 Impact factor: 6.466
Authors: Sara Verdura; Elisabet Cuyàs; Eric Cortada; Joan Brunet; Eugeni Lopez-Bonet; Begoña Martin-Castillo; Joaquim Bosch-Barrera; José Antonio Encinar; Javier A Menendez Journal: Aging (Albany NY) Date: 2020-01-04 Impact factor: 5.682